Revvity, Inc. (NYSE:RVTY) Quarterly Earnings Overview

Core Insights - Revvity, Inc. reported a quarterly EPS of $1.18, exceeding the Zacks Consensus Estimate of $1.14, but down from $1.28 in the same quarter last year [1][6] - The company's revenue for the quarter was approximately $699 million, below the estimated $762 million, yet an increase from $684.05 million reported in the same quarter the previous year [2][6] - Revvity has consistently exceeded consensus EPS estimates over the past four quarters, indicating effective management of earnings expectations [2][3] Financial Performance - The company operates in the competitive Zacks Medical Services industry and has surpassed consensus revenue estimates twice in the last four quarters [3] - Revvity has increased its annual profit forecast due to a surge in demand for its diagnostic testing kits [3] - The price-to-earnings (P/E) ratio is approximately 40.69, reflecting investor confidence in its earnings potential [4] - The price-to-sales ratio stands at about 4.10, and the enterprise value to sales ratio is around 4.95, indicating the company's valuation relative to its revenue [4] Financial Health - Revvity's debt-to-equity ratio is roughly 0.45, indicating a moderate level of debt compared to equity [5] - The current ratio of approximately 3.33 suggests strong liquidity, highlighting the company's ability to cover short-term liabilities [5] - The enterprise value to operating cash flow ratio is approximately 23.71, indicating favorable market valuation of the company's cash flow [5] - The earnings yield of about 2.46% provides insight into the return on investment for investors [5]